



# **Carotid atherosclerosis and its relationship to coronary heart disease and stroke risk in patients with type 2 diabetes mellitus**

Yan Wu, MD<sup>a,b</sup>, Jie He, MD<sup>a</sup>, Xue Sun, MD<sup>a</sup>, Yi-Ming Zhao, MD<sup>a</sup>, Han-Yu Lou, MD<sup>a</sup>, Xiao-li Ji, MD<sup>a</sup>, Xiao-Hong Pang, MD<sup>a</sup>, Li-Zhen Shan, MD<sup>a</sup>, Ying-Xiu Kang, MD<sup>a</sup>, Jun Xu, MD<sup>c</sup>, Song-Zhao Zhang, MD<sup>d</sup>, Yong-Jian Wang, MD<sup>a</sup>, Yue-Zhong Ren, MD<sup>a</sup>, Peng-Fei Shan, MD, PhD<sup>a,\*</sup>

# Abstract

Carotid atherosclerosis (CA) and carotid plaque (CP) are highly correlated with cardiovascular disease. We aimed to determine the prevalence of CA and CP and their relationship with 10-year risks of stroke and coronary heart disease (CHD) in type 2 diabetes mellitus (T2DM).

We studied 1584 T2DM patients aged 20 years and older. CA and CP were detected using ultrasonography. Ten-year stroke and CHD risk were determined using the United Kingdom Prospective Diabetes Study (UKPDS) risk engine.

The prevalence of CA and CP increased gradually with age. Men had a higher prevalence of CA than women (CA: 58.18% vs 51.54%, P < .01). The 10-year CHD risk (27.9% vs 15.4%, P < .001) and stroke risk (15.2% vs 5.70%, P < .001) were higher in patients with CA than that of those without CA. Compared with patients without CA, the odds ratios (ORs) of CHD in CA and CP group were 4.47 and 10.78 for men, and 4.19 and 5.20 for women, respectively; in the case of stroke, the OR in CA and CP group were 8.83 and 12.07 for men, and 4.35 and 4.90 for women, respectively (P < .001 for all). Multivariate binary logistic regression analysis showed that CA was an independent risk factor for CHD [OR = 2.66, 95% confidence interval (95% CI), 2.05–3.46, P < .001] and stroke (OR = 3.11, 95% CI, 2.38–4.07, P < .001).

CA and CP were prevalent in patients with T2DM and positively correlated with 10-year CHD and stroke risk. CA was an independent risk factor for 10-year CHD risk.

**Abbreviations:** ARIC = Atherosclerosis Risk in Communities, BMI = body mass index, CA = carotid atherosclerosis, CHD = coronary heart disease, CI = confidence interval, CIMT = carotid intima-media thickness, CP = carotid plaque, CVD = cardiovascular diseases, HbA1c = glycated hemoglobin, HDL-c = high-density lipoprotein cholesterol, LDL-c = low-density lipoprotein cholesterol, NS = no statistical significance, OR = odds ratio, SBP = systolic blood pressure, SD = standard deviation, T2DM = type 2 diabetes mellitus, UKPDS = United Kingdom Prospective Diabetes Study.

Keywords: carotid atherosclerosis, coronary heart disease, diabetes mellitus, stroke

# 1. Introduction

Diabetes mellitus is now an important public health concern. Worldwide, the number of individuals living with diabetes mellitus is likely to be as high as 592 million by 2035 according to the International Diabetes Federation.<sup>[1]</sup> The prevalence of diabetes is also up to 9.7% in China.<sup>[2]</sup> There is consensus that diabetes is the coronary artery disease equivalent and is one of the principal cardiovascular disease (CVD) risk factors. The risk of CVD is 2 to 4 times higher in patients with type 2 diabetes

Editor: Kei Nakajima.

The authors declare that there is no conflict of interest regarding the publication of this paper.

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.

Medicine (2017) 96:39(e8151)

Received: 17 May 2017 / Received in final form: 29 August 2017 / Accepted: 31 August 2017 http://dx.doi.org/10.1097/MD.00000000008151

YW and JH contributed equally.

Authorship: PFS will handle the production process if accepted. YW and JH conducted the study and wrote the manuscript. XS, YMZ, HYL, XLJ, XHP, LZS, YXK, and YJW conducted the study. JX performed carotid ultrasonography. SZZ undertook laboratory experiments. YZR designed the research. PFS designed the research and wrote the manuscript.

Funding/support: This study received funding from the National Natural Science Foundation of China (81370968, 81670744), the Chinese Society of Endocrinology (13040620447), the Department of Education, Zhejiang Province (Y201328533), the Natural Science Foundation of Zhejiang Province (LY14H160023), and Medical and Health Research Fund of Zhejiang Province (2017KY561).

<sup>&</sup>lt;sup>a</sup> Department of Endocrinology and Metabolism, the Second Affiliated Hospital ZheJiang University College of Medicine, <sup>b</sup> Department of Endocrinology and Metabolism, Zhejiang Greentown Cardiovascular Hospital, <sup>c</sup> Department of Ultrasound, <sup>d</sup> Department of Clinical Laboratory, the Second Affiliated Hospital ZheJiang University College of Medicine, Hangzhou, Zhejiang, P.R. China.

<sup>\*</sup> Correspondence: Peng-Fei Shan, Department of Endocrinology and Metabolism, the Second Affiliated Hospital ZheJiang University College of Medicine, Hangzhou, 88 Jiefang Rd, Zhejiang 310009, P.R. China (e-mail: pengfeishan@zju.edu.cn).

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

mellitus (T2DM) than in the general population,<sup>[3]</sup> and in recent years, CVD has become the leading cause of death in these patients in recent years.<sup>[4]</sup>

Interestingly, CVD does not develop in all patients with T2DM. T2DM patients have many CVD risk factors in addition to hyperglycemia. Among T2DM patients with CVD, 77% to 87% have hypertension, 74% to 81% have increased low-density lipoprotein cholesterol (LDL-c) levels, and 62% to 67% are overweight.<sup>[5]</sup> This high prevalence of other CVD risk factors is correlated with the increased CVD risk in patients with T2DM. Studies have indicated that hypertension has an important influence on cardiovascular outcome in T2DM patients. The United Kingdom Prospective Diabetes Study (UKPDS) showed in a multivariate analysis that the strongest independent risk factor for CVD was elevated LDL-c, followed by reduced high-density lipoprotein cholesterol (HDL-c) level.<sup>[6]</sup> In addition, cigarette smoking is an important risk factor for CVD in these patients.<sup>[7]</sup> Up to now, it is still challenging to identify individual T2DM patients who are at a high risk for CVD.

Diabetes also has a close relation to subclinical atherosclerosis.<sup>[8]</sup> Carotid atherosclerosis (CA) detected ultrasonically occurs in arteries with intimal hyperplasia. Carotid intima-media thickness (CIMT), which can be used to predict the risk of developing coronary artery stenosis in patients who are asymptomatic, is significantly greater in those with T2DM than in the general population.<sup>[9]</sup> Measurement of CIMT is simple, noninvasive and a valuable means of identifying high-risk individuals both with and without diabetes.<sup>[10]</sup> The presence of carotid plaque (CP) is an indicator of advanced atherosclerosis and can be used to predict cardiovascular risk,<sup>[11]</sup> being associated with major adverse cardiovascular events in patients with T2DM.<sup>[12]</sup> Studies also suggest that low gray-scale median of plaque echogenicity and low eicosapentaenoic acid/arachidonic acid ratio might be useful for predicting the risk of CVD in T2DM patients.<sup>[13]</sup>

We have previously investigated CA and CP in the general population.<sup>[14]</sup> There has been little research on CA and CP in patients with T2DM in China, and most studies have been conducted in populations in clinical settings and do not describe age- or gender-related differences in CA and CP.<sup>[15,16]</sup> Li et al<sup>[15]</sup> explored the prevalence and clinical characteristics of CA in newly diagnosed patients. Another study investigated the prevalence of CA and CP in patients with both T2DM and hypertension.<sup>[16]</sup> Furthermore, there is a lack of data on the use of CA to predict CHD and stroke risk in China. Thus, we aimed to assess the age- and gender-specific prevalence of CA and CP, and their correlation with 10-year risks of stroke and CHD estimated by UKPDS risk engine<sup>[17,18]</sup> in patients with T2DM.

#### 2. Methods

### 2.1. Subjects

One thousand, five hundred eighty-four T2DM patients of age 20 years and above were diagnosed according to the World Health Organization 2006 criteria, that is, fasting plasma glucose  $\geq$ 126 mg/dL and/or 2 hours plasma glucose after 75 g oral glucose tolerance test  $\geq$ 200 mg/dL<sup>[19]</sup>; or the use of any antidiabetic drug, including insulin and oral hypoglycemic agents. Patients with CHD, stroke, and overt hyperthyroidism and hypothyroidism were excluded from this study. Patients were admitted to the Second Affiliated Hospital of Zhejiang University College of Medicine, Zhejiang, China, from August 2008 to April 2013. The

study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University College of Medicine. Informed consent was obtained before examination.

All participants underwent clinical assessment including medical history and physical examination. For weight measurement, they were instructed to wear lightweight clothes. Body mass index (BMI) was calculated as body weight in kilograms divided by height in meters squared. A plane around the abdomen at the level of the halfway point between the lowest edge of the ribs and the iliac crest was used to determine abdominal circumference. Blood pressure was measured twice for each participant using a Kenz BPM SP-1 automatic blood pressure device (Suzuken Co., Ltd, Nagoya, Japan). Measurements were made on the right arm after the participant rested for  $\geq 5$  minutes; the mean value was used in the report.

## 2.2. Biochemical tests

Samples of venous blood were obtained between 6:00 and 8:00 AM after overnight fasting. Triglycerides, total cholesterol, fasting plasma glucose, LDL-c, and HDL-c levels were determined with an AU4500 automatic chemistry analyzer (Olympus Corporation, Tokyo, Japan). Glycated hemoglobin (HbA1c) was measured with a TOSOH HLC-723G8 automatic glycohemoglobin analyzer (Tosoh Corporation, Yamaguchi, Japan) and fasting C-peptide with an ADVIA Centaur XP immunoassay System (Siemens Inc., Munich, Germany).

## 2.3. Assessment of CA

The carotid artery was assessed by 6 experienced sonographers using a B-mode ultrasound imaging unit (Alpha10; Aloka Co., Ltd, Tokyo, Japan) with a 10 MHz linear arrayprobe. The sonographers, certified by the Ministry of Health of China, did not know the clinical status or biochemical test results of the participants. Longitudinal 2-dimensional images were obtained and used to determine CIMT at the far wall of the common carotid artery on 2 sides over 10 mm proximal to the bifurcation.<sup>[20]</sup>

CIMT was measured at the end of diastole as the distance between the leading edges of the first and second echogenic lines. These lines represent the lumen–intima interface and the collagen-containing upper layer of the tunic adventitia, respectively. For analysis, we used the maximum value measured between the 2 sides of the common carotid artery. The CIMT measurements were repeated 3 times a day to assess in vivo precision and reexamined after 2 weeks in 16 subjects. The IMT measurements' mean intra- and interobserver coefficients of variation were 5.9% and 7.5%, respectively. CA was considered to be present when the CIMT was greater than 1.0 mm.<sup>[21]</sup> CP was defined as CIMT greater than 1.5 mm at the carotid bulbor at the internal or common carotid artery with or without the presence of flow disturbance.<sup>[22]</sup>

#### 2.4. Calculation of risk using the UKPDS risk engine

Ten-year CHD and stroke risks were calculated for each patient using the UKPDS risk engine (v. 2.0). The model incorporates risk factors, including sex, age, HbA1c level, race, HDL-c, current smoking status, total cholesterol, systolic blood pressure (SBP), and atrial fibrillation status.<sup>[17,18]</sup> According to the results, participants in the study were considered to be at low ( $\leq$ 10%), intermediate (10–20%), or high (>20%) risk of CHD.

#### 2.5. Statistical analysis

Data were analyzed using SPSS 17.0 (IBM, Armonk, NY). The prevalence of CA and CP was determined among all participants, in males and females, and according to 10-year and 20-year age groups. Continuous variables were presented as the mean $\pm$  standard deviation (SD) or the mean with 95% confidence interval (95% CI); categorical variables were presented as the frequency with the percentage given in parentheses. Mann-Whitney tests or independent *t* tests were used to compare continuous variables among groups and  $\chi^2$  tests were used to compare proportional data. Categorical parameters and risk estimation were evaluated by Chi-squared tests. Correlations between categorical variables and risk factors were analyzed by binary logistic regression analysis. All statistical tests were 2-tailed and P < .05 was considered significant.

## 3. Results

#### 3.1. Characteristics of T2DM patients with and without CA

Table 1 summarizes biochemical and anthropometric data for the participants according to sex and the presence of CA. Patients with CA were older, had a significantly longer duration of diabetes and higher SBP, and included more ex-smokers than patients without CA. Among men with CA, waist circumference, serum total cholesterol, LDL-c, and HDL-c were similar to men without CA, triglycerides were lower, and there were more current smokers. Women with CA had significantly higher serum total cholesterol, LDL-c, and HDL-c levels and included more current smokers than those without CA. BMI, diastolic blood pressure, waist circumference, HbA1c, and fasting plasma glucose were similar in both sexes with or without CA. The prevalence of female smoker was quite low compared with male in our result (1.34% vs 40.3%, P < .001), which was similar to the epidemiological survey results in Zhejiang province in 2013, 0.78% for women, 50.78% for men.<sup>[23]</sup> Multivariate binary logistic regression analysis showed that age [odds ratio (OR)=1.086, 95% CI=1.074–1.099; P=.000], SBP (OR= 1.007, 95% CI=1.001–1.013; P=.019), duration of diabetes (OR=1.025, 95% CI=1.005–1.044; P=.012), female sex (OR=0.467, 95% CI=0.369–0.591; P=.000), and total cholesterol (OR=1.150, 95% CI=1.047–1.279; P=.005) were independently associated with CA.

## 3.2. Prevalence of CA and CP

Among all patients with T2DM, the prevalence of CA was higher in males than in females, whereas CP was similar between the 2 sexes (CA: 58.2% vs 51.5%, P < .01; CP: 31.4% vs 31.9%, P = NS). CA onset occurred during the 20 seconds in men; the prevalence of CA increased gradually from 8.24% at 20 to 39 years of age to 86.0% in individuals aged 70 to 79 years (Fig. 1A, B). The prevalence of CP was 1.18% at 20 to 39 years and 57.9% at 70 to 79 years. In women, the onset of CA occurred in the same decade as in men; its prevalence was 3.70% at 20 to 39 years and increased gradually to 76.5% at 79 to 79 years. CP occurred later in women than in men; the prevalence was 18.3% at 40 to 49 years and 56.1% at 70 to 79 years. The prevalence of CA was 1.79% to 25.6% higher in men than in women in the same age group over 50 years of age and that of CP was 1.83% to 8.82% higher.

According to our previous study,<sup>[14]</sup> the prevalence of CA in T2DM is about 10% to 20% higher than that in general population and that of CP is 6.0% to 15.8% higher.

## 3.3. Relationship between CHD risk, stroke risk, and CA

Considering all participants, the average 10-year CHD and stroke risks were higher in patients with CA than that of those without CA (27.9% vs 15.4% for CHD risk, P < .001; 15.2% vs 5.70% for stroke risk, P < .001). CHD and stroke risk are displayed according to sex and the presence of CA in Table 2. In both sexes, individuals with CA had significantly higher CHD risk, fatal CHD risk, stroke risk, and fatal stroke risk than those without CA (P < .001 for all).

Table 1

Anthropometric and biochemical data according to presence of CA and sex.

·	• •			
	N	lale	F	emale
	Non-CA	CA	Non-CA	CA
n	350	487	362	385
Age, y	49.20±11.89	$61.78 \pm 11.45^{\ddagger}$	55.46±10.81	64.88 ± 10.68 <sup>‡</sup>
BMI, kg/m <sup>2</sup>	$24.53 \pm 3.75$	$24.14 \pm 3.27$	$23.68 \pm 3.63$	23.46±3.56
Waist circumference, cm	89.33±9.93	89.13±9.70	85.83±10.72	87.24 ± 10.21
Current smoker, n (%)	157 (44.86%)	180 (36.96%)	1 (0.28%)	9 (2.34%)*
Ex-smoker, n (%)	60 (17.14%)	113 (23.20%) <sup>*</sup>	1 (0.28%)	5 (1.30%) <sup>*</sup>
Duration of diabetes, y	5.04 (4.62-5.71)	8.32 (7.89–9.05) <sup>‡</sup>	7.54 (6.90-8.20)	10.10 (9.40–10.80) <sup>‡</sup>
Systolic blood pressure, mm Hg	132.70±19.37	$139.79 \pm 19.97^{\ddagger}$	133.81 ± 20.19	$141.73 \pm 20.30^{\ddagger}$
Diastolic blood pressure, mm Hg	82.77±11.82	$82.63 \pm 11.62$	81.64±10.72	81.13±11.08
Fasting plasma glucose, mmol/L	$9.65 \pm 3.90$	$9.50 \pm 4.05$	$9.20 \pm 3.75$	9.10±3.91
HbA1c (%)	$9.99 \pm 2.46$	$9.75 \pm 2.48$	$9.45 \pm 2.38$	9.54 ± 2.39
Triglycerides, mmol/L	2.13 (1.94–2.32)	1.76 (1.66–1.86) <sup>‡</sup>	2.00 (1.84-2.16)	1.94 (1.83-2.06)
Total cholesterol, mmol/L	$4.59 \pm 1.14$	4.48±1.20	$4.67 \pm 1.08$	$4.89 \pm 1.22^{\dagger}$
HDL-c, mmol/L	$1.19 \pm 0.32$	$1.18 \pm 0.30$	$1.29 \pm 0.31$	$1.35 \pm 0.36^{\dagger}$
LDL-c, mmol/L	$2.95 \pm 0.94$	$2.85 \pm 0.97$	$2.91 \pm 0.85$	$3.09 \pm 0.96^{*}$

Data are expressed as mean ± standard deviation or mean [95% confidence interval].

BMI=body mass index, CA=carotid atherosclerosis, HbA1c=glycated hemoglobin, HDL-c=high-density-lipoprotein cholesterol, LDL-c=low-density lipoprotein cholesterol.

\* *P*<.05.

<sup>†</sup> P<.005.

 $^{\ddagger}P < .001$ . Compared with noncarotid atherosclerosis subjects of the same sex.



Figure 1. Age-related prevalence of carotid atherosclerosis (A) and carotid plaque (B) in male and female participants in the study.

## Table 2

# UKPDS score according to sex and presence of CA.

	M	Male		Female
	Non-CA	CA	Non-CA	CA
CHD risk (%) Fatal CHD risk (%) Stroke risk (%) Fatal stroke risk (%)	18.73 (17.38–20.09) 11.92 (10.76–13.09) 5.57 (4.67–6.47) 0.88 (6.75–10.75)	33.43 (31.66–35.21)* 25.96 (24.26–27.65)* 15.81 (14.35–17.26) 2.55 (2.29–2.81)*	12.16 (11.20–13.12) 8.85 (7.97–9.74) 5.84 (4.96–6.72) 0.90 (0.76–1.05)	20.83 (19.45–22.20) <sup>*</sup> 17.08 (15.76–18.40) <sup>*</sup> 14.37 (12.68–16.05) <sup>*</sup> 2.39 (2.07–2.71) <sup>*</sup>

Data are expressed as mean [95% confidence interval].

CA = carotid atherosclerosis, CHD = coronary heart disease.

\*P < .001; compared with noncarotid atherosclerosis subjects of the same sex.

CHD risk and stroke risk increased with age. In the same decade of age after 40 years, patients with CA had higher CHD risk than those without CA of the same sex. A similar relationship existed for patients younger than 70 years with respect to stroke

risk (Fig. 2). The impact of CA and CP on cardiovascular risk is summarized in Table 3. In both sexes, individuals with CA had a higher prevalence of high CHD and stroke risk than those without CA (P < .001 for all).



Figure 2. Age-related coronary heart disease (CHD), fatal CHD, stroke, and fatal stroke risks in male and female participants with carotid atherosclerosis (CA) and without carotid atherosclerosis (non-CA).

Toble 2

	Ν	High CHD risk, n (%)	Odds ratio (95% CI)	High stroke risk, n (%)	Odds ratio (95% CI)
Male					
Non-CA	350	117 (33.4%)		14 (4%)	
CA	487	337 (69.2%)	4.47 (3.34-6.00)*	131 (26.8%)	8.83 (4.99–15.63)*
CP	263	222 (84.4%)	10.78 (7.23–16.09)*	88 (35.8%)	12.07 (6.07-21.83)*
Female					
Non-CA	362	56 (15.5%)		20 (5.6%)	
CA	385	167 (43.4%)	4.19 (2.95–5.93)*	78 (22.5%)	4.35 (2.60-7.27)*
CP	238	116 (48.7%)	5.20 (3.55–7.61)*	53 (24.8%)	4.90 (2.84-8.45)*

CA = carotid atherosclerosis, CHD = coronary heart disease, CI = confidence interval, CP = carotid plaque.

\* P < .001; compared with noncarotid atherosclerosis subjects of the same sex.

The prevalence and ORs of CHD and stroke increased with increasing CA in both sexes. Compared with patients without CA, the OR of CHD in CA and CP group were 4.47 (95% CI, 3.34-6.0) and 10.78 (95% CI, 7.23-16.09) for men, and 4.19 (95% CI, 2.95-5.93) and 5.20 (95% CI, 3.55-7.61) for women, respectively (P < .001 for all). In the case of stroke, the OR in CA and CP group were 8.83 (95% CI, 4.99-15.63) and 12.07 (95% CI, 6.07–21.83) for men, and 4.35 (95% CI, 2.60–7.27) and 4.90 (95% CI, 2.84-8.45) for women, respectively (P < .001 for all). We then performed a binary logistic regression analysis with the following dependent variables: age  $\geq 50$  years, CA, male sex (female 0, male 1), elevated total cholesterol ( $\geq$ 4.5 mmol/L), hypertension, reduced blood HDL-c levels [<1.04 mmol/L (men) or <1.29 mmol/L (women)]. The independent variables were as follows: UKPDS CHD risk (>20%, high risk,  $1; \leq 20\%$ , 0) and stroke risk (>10%, high risk, 1;  $\leq 10\%$ , 0). The results showed that CA was an independent risk factor for CHD (OR = 2.66, 95% CI, 2.05–3.46, P=.000) and stroke (OR=3.11, 95% CI, 2.38–4.07, P<.001), Table 4.

In female patients, the average 10-year CHD and stroke risks of postmenopausal women were higher than pre-menopausal women [0.191 (0.181–0.202) vs 0.069 (0.060–0.078) for CHD risk, P < .001; 0.120 (0.111–0.136) vs 0.018 (0.013–0.23) for stroke risk, P < .001].

# 4. Discussion

In our sample of T2DM patients, we found that the incidence of both CP and CA increased with age and the incidences of CA and CP were higher in men than in women. Mean age, SBP, and duration of diabetes, which are risk factors for CHD, were higher in patients with CA than in those without CA. The estimated 10year risk of CHD and stroke risk increased with age. Among older patients, those with CA had a higher CHD risk than those without CA. We also found that CA was an independent risk factor for CHD risk after adjusting for age, SBP, total cholesterol, and HDL-c.

In this study, the prevalence of CA was 55.1%, and in every decade, the incidence was higher than that in the general population as determined in our previous research.<sup>[14]</sup>Several studies have demonstrated that patients with T2DM are at a higher risk for atherosclerosis than healthy subjects.<sup>[24]</sup> There were also other studies on the prevalence of CA in patients with T2DM of different clinical setting. We found that the presence of CA was independently associated with age, duration of diabetes, SBP, male sex, and total cholesterol in patients with T2DM. In a research in which the percentage of male patients was lower than our study, the prevalence of CA detected by ultrasound examination in hospitalized T2DM patents was 44.4%.<sup>[25]</sup> This value is lower than ours. This also supports that male sex is a risk factor for CA.<sup>[26]</sup> In another study in newly diagnosed T2DM patients, the prevalence of CA was 35.8%, which is lower than our finding.<sup>[15]</sup> This indicates that the prevalence of CA may be associated with the duration of diabetes, as has been demonstrated in our research. In older T2DM patients with hypertension, researchers found that CA was quite common, being observed in 62.1% of subjects, which is more than in our study.<sup>[16]</sup> Hypertension and age were risk factors for CA in our T2DM patients, which is consistent with other studies.<sup>[27]</sup>

In the general population, studies have shown that CIMT was closely related to cardiovascular risk and stroke risk. Researchers found an approximately 40% increase in CHD risk with each SD increase in CIMT.<sup>[28,29]</sup> CIMT is an even more powerful predictor for stroke risk, with an approximate increase in cerebrovascular disease of 50% to 80% for each SD increase.<sup>[30]</sup> CIMT was measured for every participant with an average

Table 4

Multivariate binary	logistic r	regression ana	vsis of r	isk factors for	or CHD an	nd stroke as	estimated using	g the UKPDS	risk engine

	CHD risk		Stroke risk		
	OR (95% CI)	Р	OR (95% CI)	Р	
Age ≥50 y	24.52 (15.64–38.42)	.000	101.78 (25.13-412.30)	.000	
Hypertension	1.46 (1.13–1.88)	.004	1.86 (1.45–2.39)	.000	
Male sex	7.51 (5.63-10.02)	.000	1.39 (1.08–1.79)	.011	
Elevated total cholesterol	2.98 (2.26–3.92)	.000	0.70 (0.54–0.90)	.005	
Reduced HDL-c	2.33 (1.78-3.07)	.000	1.09 (0.84–1.42)	.500	
CA	2.66 (2.05–3.46)	.000	3.11 (2.38–4.07)	.000	

Elevated total cholesterol (≥4.5 mmol/L); reduced HDL-c [<1.04 mmol/L (men) or <1.29 mmol/L (women)].

CA=carotid atherosclerosis, CHD=coronary heart disease, CI = confidence interval, HDL-c=high-density lipoprotein cholesterol, OR = odds ratio.

follow-up time of 5.2 years in the Atherosclerosis Risk in Communities (ARIC) study. CHD was 1.85 times more prevalent in men and 5.07 times more prevalent in women with CA than in patients without CA.<sup>[31]</sup> In a previous ARIC study that examined the relationship between CIMT and cerebrovascular disease over a mean of 7.2 years, ischemic cerebrovascular disease was more prevalent in patients with CA than in those without (2.02 times greater in women and 1.78 times greater in men).<sup>[32]</sup>

T2DM patients are at a greater risk of developing CVD than the general population and T2DM leads to increased morbidity and mortality from CVD. Epidemiologic data suggest that the cardiovascular risk attributable to T2DM remains about 2-fold increased even after adjustment for traditional risk factors such as hyperglycemia, hypertension, and hyperlipidemia.<sup>[33]</sup> Therefore, it is crucial to identify patients at a high residual risk to enable the intensification of preventive therapies in these individuals. The greater risk for CVD in T2DM patients cannot entirely be explained by traditional risk factors alone, and there have been efforts to identify and understand the link between diabetes and "non-traditional" CVD risk factors such as endothelial dysfunction, inflammation, impaired fibrinolysis, increased homocysteine levels, microalbuminuria, and vascular wall abnormalities. The relationship between CA and CHD risk has also been studied in T2DM patients in recent years.

Another important result in our study was that after adjustment for age and other risk factors for CHD, CA was independently correlated with CHD risk and stroke risk in our study. In the study by Seon et al, <sup>[27]</sup> 10-year CHD and stroke risks calculated using the UKPDS risk engine were positively associated with CIMT, which is similar to our results. 10-year CHD risk and 10-year stroke risk both increased with age.

Our study also has limitations. First, the UKPDS risk engine was developed using data obtained from newly diagnosed T2DM patients, whereas some participants in our study had diabetes of longer duration; the UKPDS risk engine is highly sensitive for predicting CHD risk in Chinese patients with diabetes, with convergent validity and good feasibility,<sup>[34]</sup> thus, using it to predict CHD and stroke risk in the participants in our study is reliable. Second, our participants were all inpatients whose glycemic control was unsatisfactory. Worldwide, most patients with T2DM fail to achieve adequate glycemic control,<sup>[25]</sup> so to some extent, our data could represent the general T2DM population. Third, this is a cross-sectional study, and a further prospective study is required to investigate the development and progression of CA and its relationship to CVD risk in T2DM patients.

In summary, we demonstrate that the prevalence of CA in T2DM patients was higher in men, was higher than in the general population, and increased with age. CA and CP were correlated with 10-year CHD and stroke risk according to the UKPDS risk engine in patients with T2DM. Furthermore, CA was independently associated with 10-year CHD risk. Because diabetes is a public health problem in global, we should pay more attention to the CHD risk of these people; thus, monitoring the progression of CA is necessary.

#### References

- International Diabetes Federation. IDF Diabetes Atlas. 6th ed. IDF, Brussels:2013.
- [2] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090–101.
- [3] Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with

non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36.

- [4] Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291–7.
- [5] The Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.
- [6] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ 1998;316:823–8.
- [7] Qin R, Chen T, Lou Q, et al. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: metaanalysis of observational prospective studies. Int J Cardiol 2013;167: 342–50.
- [8] Wagenknecht LE, D'Agostino RBJr, Haffner SM, et al. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis study. Diabetes Care 1998;21:1812–8.
- [9] Yamasaki Y, Kodama M, Nishizawa H, et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 2000;23:1310–5.
- [10] Katakami N, Kaneto H, Shimomura I. Carotid ultrasonography: a potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients. J Diabetes Investig 2014;5:3–13.
- [11] Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the cardiovascular health study. Circulation 2007;116:32–8.
- [12] Vigili de Kreutzenberg S, Fadini GP, Guzzinati S, et al. Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. Diabetes Care 2015;38:1937–44.
- [13] Ariyoshi K, Okuya S, Kunitsugu I, et al. Ultrasound analysis of gray-scale median value of carotid plaques is a useful reference index for cerebrocardiovascular events in patients with type 2 diabetes. J Diabetes Investig 2015;6:91–7.
- [14] Yin JH, Song ZY, Shan PF. Age- and gender-specific prevalence of carotid atherosclerosis and its association with metabolic syndrome in Hangzhou, China. Clin Endocrinol (Oxf) 2012;76:802–9.
- [15] Li LX, Zhao CC, Ren Y, et al. Prevalence and clinical characteristics of carotid atherosclerosis in newly diagnosed patients with ketosisonset diabetes: a cross-sectional study. Cardiovasc Diabetol 2013;16: 12–8.
- [16] Du HW, Li JY, He Y. Glycemic and blood pressure control in older patients with hypertension and diabetes: association with carotid atherosclerosis. Am J Geriatr Cardiol 2011;8:24–30.
- [17] Stevens RJ, Kothari V, Adler AI, et al. United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671–9.
- [18] Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81.
- [19] World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. World Health Organization, Geneva:2006.
- [20] Baroncini LA, de Oliveira A, Vidal EA, et al. Appropriateness of carotid plaque and intima-media thickness assessment in routine clinical practice. Cardiovasc Ultrasound 2008;6:52.
- [21] Ishizaka N, Ishizaka Y, Toda E, et al. Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance. Arterioscler Thromb Vasc Biol 2003;23:295–301.
- [22] Kitamura A, Iso H, Imano H, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke 2004;35:2788–94.
- [23] Wang L, Xu Y, Wu QQ, et al. Investigation and analysis of adult tobacco epidemic situation in Zhejiang province in 2013. Chin J Health Manage 2016; 4:96–100.
- [24] Inchiostro S, Dalfollo M, Marzano A, et al. Prevalence of diabetes and/or is chaemic heart disease in classes of increasing carotid artery atherosclerosis: an ultrasonographic study. Diabet Med 2003;20:670–6.
- [25] Li L, Yu H, Zhu J, et al. The combination of carotid and lower extremity ultrasonography increases the detection of atherosclerosis in type 2 diabetes patients. Complicat Diabetes J 2012;26:23–8.
- [26] Bartman W, Pierzchała K. Clinical determinants of carotid intima-media thickness in patients with diabetes mellitus type 2. Neurol Neurochir Pol 2012;46:519–28.

- [27] Seon CS, Min KW, Lee SY, et al. Cardiovascular risk assessment with vascular function, carotid atherosclerosis and the UKPDS risk engine in Korean patients with newly diagnosed type 2 diabetes. Diabetes Metab J 2011;35:619–27.
- [28] Chien KL, Su TC, Jeng JS, et al. Carotid artery intima-media thickness, carotid plaque and coronary heart disease and stroke in Chinese. PLoS One 2008;3:e3435.
- [29] Iglesias del SA, Bots ML, Grobbee DE, et al. Carotid intima-media thickness at different sites: relation to incident myocardial infarction; The Rotterdam Study. Eur Heart J 2002;23:934–40.
- [30] Touboul PJ, Elbaz A, Koller C, et al. Common carotid artery intimamedia thickness and brain infarction: the Etude du Profilenetiquedel'Infarctus Cerebral (GENIC) case-control study. The GENIC Investigators. Circulation 2000;102:313–8.
- [31] Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483–94.
- [32] Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000;151:478–87.
- [33] Erqou S, Kaptoge S, Perry PL, et al. Emerging Risk Factors Collaboration. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302: 412–23.
- [34] Jiao FF, Lam CL, Fung C, et al. Comparison of four cardiovascular risk prediction functions among Chinese patients with diabetes mellitus in the primary care setting. Diabetes Invest 2014;5:606–14.